title: Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms?
authors.forename: Judith
authors.initials: J
authors.lastname: Kröll-Seger
authors.forename: Anna
authors.initials: A
authors.lastname: Kaminska
authors.forename: Marie Laure
authors.initials: ML
authors.lastname: Moutard
authors.forename: Anne
authors.initials: A
authors.lastname: de Saint-Martin
authors.forename: Agnes
authors.initials: A
authors.lastname: Guët
authors.forename: Olivier
authors.initials: O
authors.lastname: Dulac
authors.forename: Catherine
authors.initials: C
authors.lastname: Chiron
mesh_terms: D002540:Cerebral Cortex / Q000002:abnormalities; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D013036:Spasms, Infantile / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D013997:Time Factors; D020888:Vigabatrin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D020888:Vigabatrin